Travere Therapeutics Stock Performance
| TVTX Stock | USD 18.18 0.07 0.38% |
Travere Therapeutics holds a performance score of 20 on a scale of zero to a hundred. The entity has a beta of 1.17, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Travere Therapeutics will likely underperform. Use Travere Therapeutics maximum drawdown, skewness, and the relationship between the total risk alpha and downside variance , to analyze future returns on Travere Therapeutics.
Risk-Adjusted Performance
20 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Travere Therapeutics are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Travere Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.64 | Five Day Return 3.9 | Year To Date Return 95.19 | Ten Year Return 92.17 | All Time Return 1.1 K |
Last Split Factor 1:9 | Last Split Date 2011-11-08 |
1 | Disposition of 514 shares by Cline Christopher R. of Travere Therapeutics at 9.5093 subject to Rule 16b-3 | 09/04/2024 |
2 | Disposition of 2490 shares by Cline Christopher R. of Travere Therapeutics at 11.52 subject to Rule 16b-3 | 09/09/2024 |
3 | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 09/12/2024 |
4 | Acquisition by Eric Dube of 360000 shares of Travere Therapeutics at 8.93 subject to Rule 16b-3 | 09/20/2024 |
5 | Is Travere Therapeutics A Risky Investment | 10/07/2024 |
6 | Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI for the Treatment of IgA Nephropathy | 10/17/2024 |
7 | Travere Therapeutics, Inc.s Shares Bounce 27 percent But Its Business Still Trails The Industry | 10/31/2024 |
8 | Travere Therapeutics Inc Q3 2024 Earnings Call Highlights Strong Sales Growth Amid ... | 11/01/2024 |
9 | Vanguard Group Incs Strategic Acquisition in Travere Therapeutics Inc | 11/05/2024 |
10 | Travere Therapeutics prices 125M equity offering | 11/08/2024 |
11 | 3 Under-the-Radar Healthcare Companies | 11/11/2024 |
12 | Deep Track Capital, LP Reduces Stake in Travere Therapeutics Inc | 11/14/2024 |
13 | ARMISTICE CAPITAL, LLC Acquires Significant Stake in Travere Therapeutics Inc | 11/15/2024 |
14 | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level - Investors Business Daily | 11/19/2024 |
| Begin Period Cash Flow | 61.7 M |
Travere |
Travere Therapeutics Relative Risk vs. Return Landscape
If you would invest 903.00 in Travere Therapeutics on August 28, 2024 and sell it today you would earn a total of 915.00 from holding Travere Therapeutics or generate 101.33% return on investment over 90 days. Travere Therapeutics is currently generating 1.1955% in daily expected returns and assumes 4.5401% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Travere, and 77% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Travere Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Travere Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Travere Therapeutics, and traders can use it to determine the average amount a Travere Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2633
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TVTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.54 actual daily | 40 60% of assets are more volatile |
Expected Return
| 1.2 actual daily | 23 77% of assets have higher returns |
Risk-Adjusted Return
| 0.26 actual daily | 20 80% of assets perform better |
Based on monthly moving average Travere Therapeutics is performing at about 20% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Travere Therapeutics by adding it to a well-diversified portfolio.
Travere Therapeutics Fundamentals Growth
Travere Stock prices reflect investors' perceptions of the future prospects and financial health of Travere Therapeutics, and Travere Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Travere Stock performance.
| Return On Equity | -2.8 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.73) % | ||||
| Operating Margin | (0.89) % | ||||
| Current Valuation | 1.71 B | ||||
| Shares Outstanding | 87.03 M | ||||
| Price To Book | 76.10 X | ||||
| Price To Sales | 7.78 X | ||||
| Revenue | 145.24 M | ||||
| Gross Profit | (31.35 M) | ||||
| EBITDA | (326.25 M) | ||||
| Net Income | (376.33 M) | ||||
| Cash And Equivalents | 553.17 M | ||||
| Cash Per Share | 8.65 X | ||||
| Total Debt | 404.78 M | ||||
| Debt To Equity | 2.60 % | ||||
| Current Ratio | 4.71 X | ||||
| Book Value Per Share | (0.39) X | ||||
| Cash Flow From Operations | (280.02 M) | ||||
| Earnings Per Share | (4.52) X | ||||
| Market Capitalization | 1.58 B | ||||
| Total Asset | 788.91 M | ||||
| Retained Earnings | (1.13 B) | ||||
| Working Capital | 438.87 M | ||||
About Travere Therapeutics Performance
Evaluating Travere Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Travere Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Travere Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 299.97 | 437.62 | |
| Return On Tangible Assets | (0.16) | (0.17) | |
| Return On Capital Employed | (0.62) | (0.59) | |
| Return On Assets | (0.14) | (0.15) | |
| Return On Equity | (0.55) | (0.53) |
Things to note about Travere Therapeutics performance evaluation
Checking the ongoing alerts about Travere Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Travere Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Travere Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 145.24 M. Net Loss for the year was (376.33 M) with loss before overhead, payroll, taxes, and interest of (31.35 M). | |
| Travere Therapeutics currently holds about 553.17 M in cash with (280.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.65. | |
| Travere Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level - Investors Business Daily |
- Analyzing Travere Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Travere Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Travere Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Travere Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Travere Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Travere Therapeutics' stock. These opinions can provide insight into Travere Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.